Orchestra BioMed Holdings, Inc. OBIO 深 沪
等待开盘 07-08 09:30:00 美东时间
3.96
-0.120
-2.94%
华盛通- 最 高4.25
- 今 开4.12
- 成交量 25.91万股
- 最 低 3.885
- 昨 收 4.08
- 总市值 2.37亿
- 52周最高 5.424
- 市盈率 静 --
- 换手率 0.43%
- 52周最低 2.20
- 委 比 -21.49%
- 总股本 5988.07万
- 历史最高 23.39
- 量 比 0.71
- 振 幅 8.95%
- 历史最低 2.20
- 每 手 1
- 风险率 0.71%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 最高1100美元，花旗、瑞穗、 Melius Research齐上调美光目标价；X-Energy获大小摩等多家机构首予“买入”评级
今日重点评级关注：TD Cowen：维持Strategy"买入"评级，目标价从395美元升至400美元；摩根士丹利：维持Cipher Digital"超配"评级，目标价从40.5美元升至42.5美元
05-20 11:55
B. Riley Securities Maintains Buy on Orchestra BioMed Hldgs, Lowers Price Target to $10
B. Riley Securities analyst Kyle Bauser maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and lowers the price target from $12 to $10.
05-20 03:44
美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Orchestra BioMed Hldgs Q1 EPS $(0.33) Beats $(0.41) Estimate, Sales $110.000K Miss $190.750K Estimate
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.41) by 19.51 percent. This is a 32.65 percent increase over losses of $(0.49) per share
05-13 04:30
Orchestra BioMed Plans To Complete Enrollment In Its BACKBEAT Study Of Atrioventricular Interval Modulation Therapy By End Of Q3; Plans To Submit Primary Endpoint Data With Medtronic In Q2
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global
05-12 20:33
Orchestra BioMed Announces Second FDA Breakthrough Device Designation For AVIM Therapy Specific To Patients With Uncontrolled Hypertension Despite Use Of Medications, Along With An Indication For A Pacemaker
Together, the two BDDs for AVIM Therapy cover indications that encompass both the broader population of patients with uncontrolled hypertension despite medication and increased cardiovascular risk as well as the specific
04-30 21:03
Orchestra BioMed Hldgs Q4 EPS $0.26 Beats $(0.39) Estimate, Sales $30.917M Beat $878.600K Estimate
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $(0.39) by 166.16 percent. This is a 160.47 percent increase over losses of $(0.43) per
03-12 20:35
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
Barclays Maintains Overweight on Orchestra BioMed Hldgs, Raises Price Target to $12
Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $11 to $12.
01-09 23:09
